Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Launches New GMP Products to the Australian Medical Cannabis Market
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Product Name : Pink Kush
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 27, 2023
Lead Product(s) : Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 31, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : National Institutes of Health
Deal Size : $16.0 million
Deal Type : Funding
MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC
Details : MediPharmto design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites, to treat hospice-eligible patients dia...
Product Name : T2:C100
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 08, 2022
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : National Institutes of Health
Deal Size : $16.0 million
Deal Type : Funding
Lead Product(s) : Cannabigerol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products
Details : New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.
Product Name : CBG/CBD
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Cannabigerol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabinoid,Cannabigerol
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products
Details : Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Cannabinoid,Cannabigerol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : McMaster University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : McMaster University researchers using MediPharm Labs’ CBD50 formula and CBD:THC 10:2 formulation, which has the same as MediPharm Labs’ CBD25, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-con...
Product Name : CBD50
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : McMaster University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : McMaster University
Deal Size : Undisclosed
Deal Type : Agreement
Details : Three initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD (cannabidiol) drug candidates for multiple indications including Pain, Insomnia associated with Major Depression, and Uremic Pruritus.
Product Name : T2:C100
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 21, 2021
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : McMaster University
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : European Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Details : Patients in Germany are now able to access GMP-certified quality medical cannabis from STADA through local pharmacies under the brand – CannabiSTADA, distributed through STADAPHARM, a direct subsidiary of STADA.
Product Name : Pink Kush
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 04, 2021
Lead Product(s) : Tetrahydrocannabinol,Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : European Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement